Paragangliomas or glomus tumours of the head and neck region are rare
somatostatin receptor-expressing neuroendocrine tumours. Precise preoperative diagnosis is of special importance in order to adequately weigh the potential benefit of the operation against the inherent risks of the procedure. In this study, the clinical value of
somatostatin receptor imaging was assessed in 19 patients who underwent
somatostatin receptor scintigraphy because of known or suspected
paraganglioma of the head and neck region. The results were compared with the results of computed tomography and/or magnetic resonance imaging, histology and clinical follow-up. [(111)In-
DTPA- D-Phe(1)]-
octreotide scintigraphy was performed 4-6 and 24 h after i.v. injection of 140-220 MBq
(111)In-octreotide. Whole-body and planar images as well as single-photon emission tomography images were acquired and lesions were graded according to qualitative tracer uptake.
Somatostatin receptor imaging was positive in nine patients, identifying
paragangliomas for the first time in three patients and recurrent disease in six patients. In one patient, a second, previously unknown
paraganglioma site was identified. Negative results were obtained in ten patients. These patients included one suffering from chronic hyperplastic
otitis externa, one with
granuloma tissue and an organised haematoma, one with an
acoustic neuroma, one with an asymmetric internal carotid artery, two with
ectasia of the bulbus venae jugularis and one with a jugular vein
thrombosis. In two patients with a strong family history of
paraganglioma, individual involvement could be excluded. In only one patient did
somatostatin receptor imaging and magnetic resonance imaging yield false negative results in respect of recurrent
paraganglioma tissue. It is concluded that
somatostatin receptor scintigraphy provides important information in patients with suspected
paragangliomas of the head and neck region and has a strong impact on further therapeutic management.